Gilead Sciences has partnered with Jounce Therapeutics to exclusively license the latter’s JTX-1811 programme, an experimental immuno-oncology therapy.
JTX-1811 is a monoclonal antibody developed to selectively reduce immunosuppressive tumor-infiltrating T regulatory (TITR) cells. It acts on CCR8, a chemokine receptor present on TITR cells.
Go deeper with GlobalData
Upon binding to CCR8, JTX-1811 targets TITR cells for reduction via enhanced antibody-dependent cellular cytotoxicity mechanism.
An investigational new drug (IND) application for the therapy is expected to be submitted in the first half of next year.
Gilead Sciences Research executive vice-president William Lee said: “We are very pleased to add, upon closing of the transaction, JTX-1811 to our pipeline of investigational immuno-oncology therapies that have the potential to transform care for patients with cancer.
“JTX-1811 is complementary to our other oncology candidates and has the potential to be first in a new class of therapies as a treatment for people with both solid tumours and haematological malignancies.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAs part of the agreement worth up to $805m, Gilead will make an $85m upfront payment and a $35m equity investment in Jounce upon completion of the transaction.
In addition, Jounce is eligible for up to an additional $685m in clinical, regulatory and commercial milestones, as well as sales royalties.
Jounce will be responsible for the development of JTX-1811 through IND clearance. Later, Gilead will hold the exclusive right to develop the drug candidate.
Jounce Therapeutics CEO and president Richard Murray said: “Gilead’s investment in Jounce and, specifically, JTX-1811 reinforces the value of our Translational Science Platform and differentiated and sustainable approach to novel immuno-oncology programmes, focused on patients with cancer who have yet to benefit from immunotherapy.”
Last month, Gilead signed a multi-year collaboration with Tango Therapeutics to discover, develop and commercialise targeted immune evasion therapies for cancer patients.
